i. ■ REFERENCES

1. European Medicines Agency. Revised priority list for studies on off-patent paediatric medicinal products. August 2013. https://www.ema.europa.eu/en/documents/other/revised-priority-list-studies-patent-paediatric-medicinal-products_en.pdf. Accessed July 24, 2019.
2. Aspen Pharmacare Canada Inc. Propofol Product Monograph. August 2017. pdf.hres.ca/dpd_pm/00040632.PDF. Accessed July 24, 2019.
3. Brody T. Drug–Drug Interactions. In: FDA’s Drug Review Process and the Package Label . Elsevier; 2018:255-335. doi:10.1016/B978-0-12-814647-7.00007-5
4. Guitton J, Buronfosse T, Desage M, et al. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. British Journal of Anaesthesia . 1998;80(6):788-795. doi:10.1093/bja/80.6.788
5. Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics . 2019;58(2):189-211. doi:10.1007/s40262-018-0681-2
6. Rakhmanina N, Vandenanker J. Pharmacological research in pediatrics: From neonates to adolescents. Advanced Drug Delivery Reviews . 2006;58(1):4-14. doi:10.1016/j.addr.2005.12.001
7. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental Pharmacology - Drug Disposition, Action, and Therapy in Infants and Children. New England Journal of Medicine . 2003;349(12):1157-1167. doi:10.1056/NEJMra035092
8. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates.British Journal of Anaesthesia . 2007;99(6):864-870. doi:10.1093/bja/aem294
9. Troutman JA, Sullivan MC, Carr GJ, Fisher J. Development of growth equations from longitudinal studies of body weight and height in the full term and preterm neonate: From birth to four years postnatal age.Birth Defects Research . 2018;110(11):916-932. doi:10.1002/bdr2.1214
10. Wang C, Peeters MYM, Allegaert K, Danhof M, Knibbe CAJ. A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span. 2012;29:1570-1581. doi:10.1007/s11095-012-0668-x
11. Eleveld DJ, Colin P, Absalom AR, Struys MMRF. Pharmacokinetic–pharmacodynamic model for propofol for broad application in anaesthesia and sedation. British Journal of Anaesthesia . 2018;120(5):942-959. doi:10.1016/j.bja.2018.01.018
12. Sepúlveda P, Cortínez LI, Sáez C, et al. Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children.British Journal of Anaesthesia . 2011;107(4):593-600. doi:10.1093/bja/aer198
13. Smits A, Thewissen L, Caicedo A, Naulaers G, Allegaert K. Propofol Dose-Finding to Reach Optimal Effect for (Semi-)Elective Intubation in Neonates. The Journal of Pediatrics . 2016;179:54-60.e9. doi:10.1016/j.jpeds.2016.07.049
14. Allegaert K, Tibboel D, Naulaers G, et al. Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed. European Journal of Clinical Pharmacology . 2003;59(2):87-90. doi:10.1007/s00228-003-0585-3
15. Seno H, He Y-L, Tashiro C, Ueyama H, Mashimo T. Simple high-performance liquid chromatographic assay of propofol in human and rat plasma and various rat tissues. Journal of Anesthesia . 2002;16(1):87-89. doi:10.1007/s540-002-8101-8
16. Qi B, Nicolai J, Smits A, et al. A sensitive liquid chromatography method for analysis of propofol in small volumes of neonatal blood.Journal of Clinical Pharmacy and Therapeutics . 2019;[epub ahead of print]. doi:10.1111/jcpt.13038
17. Germovsek E, Barker CIS, Sharland M, Standing JF. Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Br J Clin Pharmacol . 2017;83(4):777-790. doi:10.1111/bcp.13160
18. Richards FJ. A Flexible Growth Function for Empirical Use.Journal of Experimental Botany . 1959;10(29):290-300.
19. Michelet R, Van Bocxlaer J, Allegaert K, Vermeulen A. The use of PBPK modeling across the pediatric age range using propofol as a case.J Pharmacokinet Pharmacodyn . 2018;45(6):765-785. doi:10.1007/s10928-018-9607-8
20. Allegaert K, Vancraeynest J, Rayyan M, et al. Urinary propofol metabolites in early life after single intravenous bolus. British Journal of Anaesthesia . 2008;101(6):827-831. doi:10.1093/bja/aen276
21. Smits A, Verbesselt R, Kulo A, Naulaers G, de Hoon J, Allegaert K. Urinary metabolites after intravenous propofol bolus in neonates.Eur J Drug Metab Pharmacokinet . 2013;38(2):97-103. doi:10.1007/s13318-012-0109-6
22. Rigby-Jones AE, Nolan JA, Wright PMC. Pharmacokinetics of Propofol Infusions in Critically Ill Neonates, Infants, and Children in an Intensive Care Unit. 2002;97(6):8.
23. Saint-Maurice C, Cockshott ID, Douglas EJ, Ricjard MO, Harmey JL. Pharmacokinetics of Propofol in Young Children atfer a Single Dose.British Journal of Anaesthesia . 1989;63(6):667-670. doi:10.1093/bja/63.6.667
24. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NHG. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. British Journal of Anaesthesia . 2004;92(2):208-217. doi:10.1093/bja/aeh042
25. Choonara IA, McKAY P, Hain R, Rane’ A. Morphine metabolism in children. Br J Clin Pharmac . 1989;28:599-604.
26. Miyagi SJ, Milne AM, Coughtrie MWH, Collier AC. Neonatal Development of Hepatic UGT1A9: Implications of Pediatric Pharmacokinetics.Drug Metab Dispos . 2012;40(7):1321-1327. doi:10.1124/dmd.111.043752
27. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults.Gut . 2002;50(2):259-265. doi:10.1136/gut.50.2.259
28. Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of Fat-Free Mass in Children. Clinical Pharmacokinetics . 2015;54(11):1169-1178. doi:10.1007/s40262-015-0277-z
29. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of Lean Bodyweight: Clinical Pharmacokinetics . 2005;44(10):1051-1065. doi:10.2165/00003088-200544100-00004